Regeneron Pharmaceuticals Inc

Regeneron’s new gene‑therapy approval and U.S. MFN pricing pact promise free treatment for rare hearing loss, boosting accessibility, market share, and investor confidence.

Regeneron’s Q1 highlights insider sales, upcoming Phase 3 allergy data, and a Samsung Bioepis settlement—investors weigh risks against a strong oncology pipeline and institutional confidence.

Regeneron’s stock near 2025 peak as Morgan Stanley sees policy risks easing, boosting investor confidence in its biotech pipeline and valuation.

Regeneron’s eye‑care and immunology pipeline fuels a $26.5 billion AMD market; analysts lift price targets, underscoring robust growth and solid financials.

Regeneron’s $2 billion facility upgrade, analyst “Buy” boost, and oncology‑COPD‑pruritus‑sepsis pipeline signal robust growth and shareholder value.

Regeneron’s Q3 surge amid a UK court setback shows it’s still a top immuno‑oncology player, but eye‑care biosimilar competition could hit margins—find out how its strategy could protect investors.

Regeneron’s Phase‑2 FXI antibody data and Dupixent’s AFRS study hit major milestones, boosting its stock and proving the company’s clinical and financial strength.

Regeneron Pharmaceuticals is navigating a strategic shift, balancing the consolidation of its core assets with ambitious expansion into multispecific antibodies and U.S. manufacturing investments, amidst a competitive landscape and manufacturing cha…

Regeneron Pharmaceuticals reported a strong third-quarter performance, exceeding Wall Street expectations with adjusted earnings per share of $11.83 and revenue of $3.75 billion, driven by the continued success of its flagship drug Dupixent.

Regeneron Pharmaceuticals has discontinued its development of the 2seventy lymphoma CAR-T therapy, citing a reassessment of its clinical and commercial prospects, and will instead focus on its core portfolio of biologics.